GURUFOCUS.COM » STOCK LIST » USA » NAS » NovoCure Ltd (NAS:NVCR) » Definitions » Scaled Net Operating Assets
Switch to:

NovoCure (NAS:NVCR) Scaled Net Operating Assets

: 0.05 (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NovoCure's operating assets for the quarter that ended in Sep. 2023 was $225.1 Mil. NovoCure's operating liabilities for the quarter that ended in Sep. 2023 was $162.6 Mil. NovoCure's Total Assets for the quarter that ended in Jun. 2023 was $1,159.0 Mil. Therefore, NovoCure's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was 0.05.


NovoCure Scaled Net Operating Assets Historical Data

The historical data trend for NovoCure's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.16 0.16 0.05 0.05

NovoCure Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Scaled Net Operating Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.05 0.05 0.05

Competitive Comparison

For the Medical Devices subindustry, NovoCure's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure Scaled Net Operating Assets Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NovoCure's Scaled Net Operating Assets falls into.



NovoCure Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NovoCure's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(222.223-166.207)/1139.495
=0.05

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1191.648 - 969.425
=222.223

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=750.478 - 584.271 - 0
=166.207

NovoCure's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2023 )
=(Operating Assets (Q: Sep. 2023 )-Operating Liabilities (Q: Sep. 2023 ))/Total Assets (Q: Jun. 2023 )
=(225.105-162.609)/1159.015
=0.05

where

Operating Assets(Q: Sep. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1146.353 - 921.248
=225.105

Operating Liabilities(Q: Sep. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=752.649 - 590.04 - 0
=162.609

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovoCure Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of NovoCure's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (NAS:NVCR) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Executives
Pritesh Shah officer: Chief Commercial Officer C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Michal Nath Puri officer: Chief Human Resources Officer BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039
Wilhelmus Cm Groenhuysen officer: Chief Financial Officer C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654
Ashley Cordova officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Arye Barak Ben officer: General Counsel TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Kristin Stafford director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Frank X Leonard officer: President, CNS Cancers US 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
William Patrick Burke officer: Chief Human Resources Officer 195 COMMERCE WAY, PORTSMOUTH NH 03801
Uri Weinberg officer: Chief Innovation Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Allyson J Ocean director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Asaf Danziger director, officer: Chief Executive Officer 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302
Ely Benaim officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
William F Doyle director, 10 percent owner
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025